Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2025 11:57 ET | Source: Spherix Global Insights

Hemophilia Specialists Raise the Bar: Quality of Life and Innovation Drive Market Reordering

EXTON, PA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Hematologists across the United States are redefining what “success” looks like in hemophilia treatment, according to the latest findings from Market...
September 17, 2025 07:15 ET | Source: Arch Biopartners

Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)

Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly...
August 27, 2025 12:50 ET | Source: BioNTech SE

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1Shipping of the LP.8.1-adapted vaccine will...
August 25, 2025 07:30 ET | Source: Custom Market Insights

[Latest] Global Targeted Drug Delivery Market Size/Share Worth USD 39.6 Billion by 2034 at a 15.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Targeted Drug Delivery Market Size, Trends and Insights By Technology...
August 21, 2025 12:30 ET | Source: Custom Market Insights

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Biologics and Biosimilars Market Size, Trends and Insights By Product Type...
August 05, 2025 00:30 ET | Source: Custom Market Insights

[Latest] Global Paracetamol Market Size/Share Worth USD 1460.23 Million by 2034 at a 5.24% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Paracetamol Market Size, Trends and Insights By Product Type (Tablet, Capsule,...
July 24, 2025 07:00 ET | Source: Levin Papantonio

Pfizer’s ‘Depo-Provera’ Increases Risk of Brain Tumours 3.5 Times Compared to Combined Birth Control Pill According to New Study as Litigation Overseen by Levin Papantonio Rises to Over 550 Lawsuits

Pfizer’s ‘Depo-Provera’ increases risk of brain tumours 3.5 times compared to combined birth control pill, according to new study.
June 12, 2025 15:11 ET | Source: Berger Montague

INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)

PHILADELPHIA, June 12, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Pfizer Inc. (“Pfizer” or the “Company”) (NYSE: PFE) about an investigation into Pfizer’s Board of Directors...
June 10, 2025 04:30 ET | Source: Custom Market Insights

[Latest] Global Neoantigen Cancer Vaccine Market Size/Share Worth USD 1.98 Billion by 2034 at a 15.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, June 10, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Neoantigen Cancer Vaccine Market Size, Trends and Insights By Product...
June 06, 2025 07:00 ET | Source: Arvinas Inc.

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published...